Axcella Health Inc. (AXLA)
| Market Cap | 1.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -50.03M |
| Shares Out | 2.95M |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,782 |
| Open | 0.360 |
| Previous Close | 0.440 |
| Day's Range | 0.360 - 0.510 |
| 52-Week Range | 0.340 - 41.250 |
| Beta | 0.58 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Dec 5, 2023 |
About AXLA
Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to ... [Read more]
Financial Performance
Financial StatementsNews
Axcella Announces Reverse Stock Split Effective September 19, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using com...
Axcella Granted Patent for Long COVID Fatigue Treatment
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using com...
Axcella Reports Second Quarter Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using com...
Axcella Reports First Quarter Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous ...
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous ...
Axcella Therapeutics to Participate in the SVB Securities' 2023 Global Biopharma Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenou...
Axcella Announces Program Reprioritization and Corporate Restructuring
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulato...
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
CAMBRIDGE, Mass.
Axcella Reports Third Quarter Financial Results and Provides Business Update
CAMBRIDGE, Mass.
Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022
CAMBRIDGE, Mass.
Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
CAMBRIDGE, Mass.
Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members
CAMBRIDGE, Mass.
Axcella's stock is up 10% after sharing new data for its NASH treatment
Shares of Axcella Therapeutics Inc. AXLA, +6.79% gained 10.9% in premarket trading on Thursday after the biotech said its experimental treatment for nonalcoholic steatohepatitis (NASH) showed statisti...
Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous ...
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metab...
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge...
Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge...
Insiders Buy Over $7M Of 3 Penny Stocks
The US Federal Reserve, on Wednesday, raised its target fed funds rate by 0.25%, its first interest rate hike since 2018. Investors, meanwhile, focused on some notable insider trades When insiders pur...
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge...
Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endoge...